Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | GABRE | P78334 | 1/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501517 | 0.87 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17427768 | 0.87 | IKBKB (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17339728 | 0.85 | IKBKB (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11431563 | 0.84 | IKBKB (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28559696 | 0.83 | SMN1; SMN2 (0.41) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL634174 | 0.83 | KDM4E (0.58) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL9632112 | 0.83 | RAB9A (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29248333 | 0.81 | KDM4E (0.44) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL11548945 | 0.80 | KDM4E (0.43) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL17747457 | 0.80 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697975-A | Herbicidal cinnoline derivatives | 先正达农作物保护股份公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20160009652-A1 | SMALL-MOLECULE MODULATORS OF MELANIN EXPRESSION | UNIV ROCHESTER (US) | 2016-01-14 | — | — | US | disclosed |
| US-9212205-B2 | Nucleic acid binding compounds and methods of use | UNIVERSITY OF ROCHESTER (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212205-B2 | Nucleic acid binding compounds and methods of use | UNIVERSITY OF ROCHESTER (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212205-B2 | Nucleic acid binding compounds and methods of use | UNIVERSITY OF ROCHESTER (US) | 2015-12-15 | — | — | US | disclosed |
| US-9162984-B2 | Small-molecule modulators of melanin expression | UNIVERSITY OF ROCHESTER (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2552207-A1 | SWEET FLAVOR MODIFIER | Senomyx, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123693-A1 | SWEET FLAVOR MODIFIER | SENOMYX, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20100266677-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100266677-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2009015384-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015384-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008121850-A2 | SMALL-MOLECULE MODULATORS OF MELANIN EXPRESSION | UNIVERSITY OF ROCHESTER (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | disclosed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | disclosed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | disclosed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | disclosed |
| EP-0070767-B1 | QUINOLINE DERIVATIVES, THEIR SALTS, THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1985-04-10 | — | — | EP | disclosed |
| EP-0070767-A1 | Quinoline derivatives, their salts, their preparation, their use as medicines and compositions containing them | ROUSSEL-UCLAF (FR) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009652-A1 | SMALL-MOLECULE MODULATORS OF MELANIN EXPRESSION | TYR, MITF, MC1R | GABRP 560/4885GABRD 3216/4885GABRA1 2175/4885 |
| US-20100266677-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | SLIRP, HNRNPF, SUB1 | GABRP 3617/4885GABRD 2435/4885GABRA1 3720/4885 |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | GABRP 4629/4885GABRD 4643/4885GABRA1 4055/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | GABRP 4399/4885GABRD 4476/4885GABRA1 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.